According to http://phytosciencenigeria.com.ng/2017/11/15/its-world-diabetes-day-but-what-is-biotech-doing-to-fight-the-disease/

Diabetes is now a major epidemic, with 425 million people living with the condition. Luckily, biotech is working on ways to stop it in its tracks.

Not only is it Antibiotic Awareness Week, but today is World Diabetes Day. This year’s theme draws attention to diabetes in women and the right to live a healthy life. The International Diabetes Federation wants to highlight the importance of confronting the disease as a major global health issue, which places a massive burden on healthcare systems – with global spending reaching $727B (€620B).

Diabetes currently affects 425 million people, with 1 in 2 of these currently undiagnosed so unable to be properly treated. Of the 425 million, 199 million are women, who experience problems during pregnancy, with 1 in 6 births affected by hyperglycemia.

To play our part in the event, we wanted to shed light on the many different ways biotech is standing up to the disease.
Type 1 Diabetes

Type 1 diabetes is an autoimmune disease where the body’s immune system attacks and destroys the insulin-producing beta cells in the pancreas, meaning blood glucose can no longer be regulated. With patients currently having to cope with daily injections, a new, less traumatic approach would gain access to a market predicted to be worth almost $26B (€22B) by 2024.

Cell therapy has the potential to replace the cells damaged by type 1 diabetes, and Evotec and Sanofi have proof-of-concept for their stem cell-derived beta cells.
Two Swedish biotechs, Betagenon and Baltic Bio, have developed an AMP-activated protein kinase activator, which suppresses energy consumption to restore balance. So far, the candidate has achieved promising results during a Phase IIa study.

Get to know more about stem cell treatment of diabetes at www.phytosciencenigeria.com.ng or call +2348084187162